June 15, 2020 02:28 PM EDTUpdated June 16, 10:08 AM

The FDA backs off a hasty — and damaging — emergency OK for a potentially dangerous Covid-19 drug

The FDA rushed in with an emergency authorization less than 3 months ago to allow anxious, frightened people the opportunity of using two malaria drugs …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

The FDA backs off a hasty — and damaging — emergency OK for a potentially dangerous Covid-19 drug

This article is available only to Premium subscribers

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

The FDA backs off a hasty — and dam­ag­ing — emer­gency OK for a po­ten­tial­ly dan­ger­ous Covid-19 drug

This article is available only to Premium subscribers

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

The FDA backs off a hasty — and damaging — emergency OK for a potentially dangerous Covid-19 drug

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market